114 results
Page 4 of 6
8-K
EX-99.2
jbnegokw7r7nd gnzyks
8 Sep 20
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
9:16am
8-K
EX-4.1
zr0baixt7tns
6 Aug 20
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
y0blw99e4
6 Aug 20
Entry into a Material Definitive Agreement
7:00am
8-K
EX-10.1
ct23hj 72ugg
22 Jun 20
Entry into a Material Definitive Agreement
7:44am
S-3ASR
jidqhho
28 Jan 20
Automatic shelf registration
12:00am
8-K
EX-99.1
yk65lgquwz 8cf8kr0hu
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
EX-10.1
fn9wtxv36r6cj95gjog
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
EX-99.1
o9h25aunod2g9lio3
13 Dec 19
Regulation FD Disclosure
4:16pm
8-K
EX-10.1
yssph
5 Dec 19
Athenex Announces $60 Million Private Placement
8:05am
8-K
EX-99.1
8vbszrrnkjuqhhruvy2f
9 Sep 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
5lkpuf 1jwluwolopd
7 Aug 19
Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer
6:32am
8-K
EX-99.2
effoz
7 Aug 19
Positive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer
6:32am